Print Page  Close Window
8-K
PARATEK PHARMACEUTICALS, INC. filed this Form 8-K on 01/04/2019
Entire Document
 

Slide 30

Paratek: 2019 & 2024 NUZYRA Net Product Revenue Guidance 2019 Guidance Assumptions NUZYRA Net Product Revenues $10 to $13 Million Excludes anticipated revenues from the SEYSARA U.S. royalty stream and potential Department of Defense grant revenues Assumes a U.S. NUZYRA WAC price of $345 per vial for IV and WAC price of $197.50 per tablet for oral formulation​, a February 2019 U.S. launch (11 months), no ex-US omadacycline and sarecycline revenues, and a modest NUZYRA uptake as Company works through anticipated antibiotic launch dynamics . 2024 Guidance Assumptions NUZYRA Net Product Revenues Approximately $500 Million Excludes anticipated revenues from the SEYSARA U.S. royalty stream and potential Department of Defense grant revenues Assumes a hospital launch only, no oral only CABP label, no additional indications including UTI, no ex-US omadacycline and sarecycline revenues, and no revenues from Department of Defense